AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Public ClinicalTrials.gov record NCT00770536. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Study identification
- NCT ID
- NCT00770536
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 103 participants
Conditions and interventions
Conditions
Interventions
- A1: AMG 386 10 mg/kg + Liposomal doxorubicin Drug
- A3: AMG 386 15mg/kg + Liposomal doxorubicin Drug
- B1: AMG 386 10 mg/kg + Topotecan Drug
- B3: AMG 386 15mg/kg + Topotecan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2008
- Primary completion
- Dec 31, 2011
- Completion
- May 31, 2015
- Last update posted
- Sep 28, 2015
2009 – 2015
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Tucson | Arizona | 85724-5024 | — |
| Research Site | Sacramento | California | 95817 | — |
| Research Site | Orlando | Florida | 32806 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Saint Louis Park | Minnesota | 55426 | — |
| Research Site | Winston-Salem | North Carolina | 27103 | — |
| Research Site | Bismarck | North Dakota | 58501 | — |
| Research Site | Columbus | Ohio | 43219 | — |
| Research Site | Philadelphia | Pennsylvania | 19111 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00770536, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2015 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00770536 live on ClinicalTrials.gov.